在新辅助化疗后残留疾病的HR+/HER2-BC患者中PI3K/PTEN/mTOR通路的动态跟踪和预后价值:一项队列研究

Federica Miglietta1,2, Valentina Carraro3, Ottavia Amato4,2

  • 1Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, Padova, Italy federica.miglietta@unipd.it.

PubMed
概括

激素受体阳性乳腺癌中的PI3K/PTEN/mTOR通路在新辅助化疗期间是动态的. 了解超出PIK3CA突变的途径改变对于预测治疗反应至关重要.